Internal Medicine, Hematology & Oncology · Mechanicsville, VA
NPI
1265566772
Since 2007
Specialty
Internal Medicine, Hematology & Oncology
Code 207RH0003X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
7501 Right Flank Rd, Suite 600
Mechanicsville, VA, 23116
Phone (804) 559-2489
Groups this clinician bills Medicare through
Medicare paid, 2024
$2.0M
91,888 services
Medicare patients, 2024
689
Average age 76
Drug cost, 2024
$3.0M
695 prescriptions
Company payments, 2025
$1,119
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Seaborn M Wade III was code J9271 (injection, pembrolizumab, 1 mg), 9,600 times for 21 patients. In total Seaborn M Wade III billed 91,888 services in 112 codes, and Medicare paid $2.0M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2021-05-24.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J9271 Injection, pembrolizumab, 1 mg | Office | 9,600 | 21 | $44.79 | $430K |
| Q0138 Injection, ferumoxytol, for treatment of iron deficiency anemia, 1 mg (non-esrd use) | Office | 8,160 | 15 | $0.24 | $1,938 |
| J0897 Injection, denosumab, 1 mg | Office | 7,260 | 46 | $20.65 | $150K |
| J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 7,200 | 11 | $39.31 | $283K |
| J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 6,880 | 52 | $6.27 | $43K |
| J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg | Office | 2,250 | 11 | $35.45 | $80K |
| J1100 Injection, dexamethasone sodium phosphate, 1 mg | Office | 1,056 | 52 | $0.09 | $93.7 |
| J1750 Injection, iron dextran, 50 mg | Office | 830 | 69 | $13.56 | $11K |
| 99213 Office E&M - Established | Office | 532 | 323 | $59.43 | $32K |
| J2469 Injection, palonosetron hcl, 25 mcg | Office | 400 | 12 | $0.72 | $288 |
| 96372 Injection Administration | Office | 394 | 133 | $10.39 | $4,093 |
| 88185 Surgical Pathology Examination | Office | 357 | 15 | $17.24 | $6,156 |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 295 | 221 | $12.37 | $3,649 |
| 99214 Office E&M - Established | Office | 229 | 143 | $88.77 | $20K |
| 96375 Injection Administration | Office | 201 | 63 | $10.89 | $2,188 |
By year: 2022 $2.4M for 153,126 services; 2023 $1.8M for 128,042 services; 2024 $2.0M for 91,888 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 88185 Surgical Pathology Examination | 357 | 15 | $17.24 | $6,156 |
| 88184 Surgical Pathology Examination | 15 | 15 | $59.54 | $893 |
Medicare prescription drug claims, 2024
In 2024, the drug Seaborn M Wade III prescribed most often to Medicare patients was Eliquis (Apixaban), with 86 prescriptions and refills. In total Seaborn M Wade III wrote 695 Medicare prescriptions that cost $3.0M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Eliquis Apixaban | 86 | 104 | 13 | $60K |
| Xarelto Rivaroxaban | 64 | 114 | 12 | $60K |
| Revlimid Lenalidomide | 41 | 41 | Under 11 | $662K |
| Hydroxyurea Generic | 38 | 99 | 13 | $974 |
| Imbruvica Ibrutinib | 38 | 38 | Under 11 | $598K |
| Warfarin Sodium Generic | 36 | 93 | Under 11 | $313 |
| Bosulif Bosutinib | 32 | 32 | Under 11 | $598K |
| Gabapentin Generic | 25 | 55 | Under 11 | $376 |
| Lenalidomide Generic | 24 | 24 | Under 11 | $432K |
| Letrozole Generic | 24 | 59 | Under 11 | $202 |
| Dexamethasone Generic | 21 | 26 | 15 | $370 |
| Oxycodone Hcl Generic | 19 | 19 | Under 11 | $258 |
| Pomalyst Pomalidomide | 18 | 18 | Under 11 | $407K |
| Imatinib Mesylate Generic | 17 | 17 | Under 11 | $6,257 |
| Potassium Chloride Generic | 13 | 13 | Under 11 | $45.61 |
Brand drugs: 302 claims; generic drugs: 393 claims; opioid claims: 38.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Seaborn M Wade III $1,119 ($1,119 in general payments such as food, travel and fees) from 27 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $142.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 6 | $142 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $112 |
| Merck Sharp & Dohme LLC MRK | 4 | $95.97 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 3 | $79.33 |
| Ipsen Biopharmaceuticals, Inc IPN.PA | 2 | $68.37 |
| E.R. Squibb & Sons, L.L.C. BMY | 3 | $57.46 |
| Legend Biotech USA Inc. LEGN | 2 | $56.17 |
| Incyte Corporation INCY | 2 | $49.4 |
| Pfizer Inc. PFE | 2 | $46.6 |
| BeOne Medicines USA, Inc. ONC | 1 | $33.47 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.